Y-mAbs Therapeutics

• US Public Offering on the Nasdaq Global Market comprising 2,439,025 shares of common stock, at a public offering price of USD 41.00 per share
• Gross proceeds of the base deal amount to USD 100 million. Following the exercise of the over-allotment option in full, an additional 365,853 shares of common stock were placed at the public offering price, bringing the total gross proceeds to USD 115 million
• Executed on the back of momentum as Y-mAbs achieved a number of clinical and regulatory milestones over the past several months
• Received strong support from European and US investors, resulting in a multiple times covered orderbook
• Marks Kempen & Co’s fourth transaction for a Danish life sciences company since 2019, following the US IPO of Genmab (2019), the US Public Offering of Ascendis Pharma (2020), and the US IPO of Galecto (2020)
• In 2021 year to date, Kempen & Co has already executed 6 transactions for European life sciences companies

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. The Company has a broad and advanced product pipeline, including one FDA approved product, DANYELZA® (naxitamab-gqgk), which targets tumours that express GD2, and one pivotal-stage product candidate, omburtamab, which targets tumours that express B7-H3.

In the last twelve months, Kempen & Co has successfully completed a large number of transactions in its Life Sciences & Healthcare franchise. Recent transactions include:

• Co-Manager in the USD 115 million US Public Offering by Autolus Therapeutics
• Joint Global Coordinator and Joint Bookrunner in the €22.5 million Capital Increase by Sequana Medical
• Co-Manager in the USD 165 million Nasdaq Initial Public Offering by Pharvaris
• Passive Bookrunner in the USD 518 million US Public Offering by CureVac
• Lead Manager in the USD 120 million US Public Offering by Merus 
• Financial Adviser to DCprime in its merger with Immunicum 
• Joint Bookrunner in the SEK 564 million Capital Increase by Cantargia
• Sole Financial Adviser in the sale of Galapagos’ service operation, Fidelta, to Selvita for a total consideration of €31.2 million
• Placement Agent in Investinor’s Secondary Sell-Down of c. 4 million shares in Calliditas Therapeutics
• Lead Manager in the USD 85.0 million Nasdaq Initial Public Offering by Galecto
• Joint Bookrunner in the €31.0 million Capital Increase by Sensorion
• Bookrunner in the USD 245 million Nasdaq Initial Public Offering by Curevac
• Co-Manager in the USD 49.0 million US Public Offering by Centogene
• Joint Bookrunner in the SEK 1.11 billion Capital Increase by Hansa Biopharma
• Joint Bookrunner in the CHF 80.2 million Capital Increase by Molecular Partners
• Co-Manager in the USD 690 million US Public Offering by Ascendis Pharma
• Financial advisor in Immatics’ business combination with Arya Sciences Acquisition Corp., thereby becoming a Nasdaq listed company and securing USD 253 million
• Joint Global Coordinator and Joint Bookrunner in the €61.8 million Initial Public Offering by Hyloris Pharmaceuticals
• Joint Bookrunner in the €20.0 million Capital Increase by Oryzon Genomics
• Joint Global Coordinator and Joint Bookrunner in the SEK 487 million Capital Increase by BioInvent
• Joint Global Coordinator and Joint Bookrunner in the c. SEK 400 million Capital Increase by Immunovia
• Co-Manager in the USD 862 million Global Offering by argenx
• Joint Bookrunner in the SEK 1.41 billion Capital Increase by Oncopeptides